L-tryptophan in the treatment of levodopa induced psychiatric disorders
- PMID: 17894051
L-tryptophan in the treatment of levodopa induced psychiatric disorders
Abstract
Nine patients with levodopa induced psychiatric side effects were treated with L-Tryptophan in a single blind controlled study. In all patients levodopa therapy was continued and no sedative agents were given. In 8 patients all psychiatric side effects cleared within 48 hours, and without reoccurrence of these symptoms on an 8 month follow up. Only one patient did not respond to the treatment, but this patient proved to have a psychotic depression which was unrelated to levodopa therapy. Six patients with levodopa induced psychiatric disorders were used as control subjects and were not treated with L-Tryptophan. In these patients mental changes subsided only after levodopa had been discontinued for a period of 2 to 8 weeks. The rationale for treatment with L-Tryptophan is based on the findings of decreased serotonin content of the brain after levodopa treatment. This was documented by animal studies and reflected by changes in the spinal fluid concentration of 5-hydroxyindolacetic acid before and after L-Tryptophan treatment. This study confirms the results described by Dr. Birkmayer who treated levodopa induced psychosis first in 1972 in this manner.
Similar articles
-
[Psychiatric complications of L-dopa: physiopathology and treatment].Rev Neurol. 1997 Aug;25 Suppl 2:S157-62. Rev Neurol. 1997. PMID: 9280683 Review. Spanish.
-
Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.Arch Neurol. 2006 Feb;63(2):205-9. doi: 10.1001/archneur.63.2.205. Arch Neurol. 2006. PMID: 16476808
-
Zotepine in levodopa-induced Psychosis.Mov Disord. 1995 Nov;10(6):795-7. doi: 10.1002/mds.870100615. Mov Disord. 1995. PMID: 8750001 No abstract available.
-
[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].Rev Neurol (Paris). 2009 Aug-Sep;165(8-9):718-27. doi: 10.1016/j.neurol.2008.11.017. Epub 2009 Jan 15. Rev Neurol (Paris). 2009. PMID: 19150100 Clinical Trial. French.
-
Levodopa in the early treatment of Parkinson's disease.Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S17-20. doi: 10.1016/S1353-8020(09)70006-9. Parkinsonism Relat Disord. 2009. PMID: 19131036 Review.
Cited by
-
Nucleus ruber and L-dopa psychosis: biochemical post-mortem findings.J Neural Transm. 1974;35(2):93-116. doi: 10.1007/BF01250738. J Neural Transm. 1974. PMID: 4844103 No abstract available.
-
Nutrition and schizophrenia.Can Fam Physician. 1975 Apr;21(4):78-82. Can Fam Physician. 1975. PMID: 20469184 Free PMC article.
-
Tryptophan in alcoholism treatment II: inhibition of the rat liver mitochondrial low Km aldehyde dehydrogenase activity, elevation of blood acetaldehyde concentration and induction of aversion to alcohol by combined administration of tryptophan and benserazide.Alcohol Alcohol. 2011 Nov-Dec;46(6):661-71. doi: 10.1093/alcalc/agr135. Epub 2011 Sep 6. Alcohol Alcohol. 2011. PMID: 21896551 Free PMC article.
-
L-Tryptophan: Biochemical, nutritional and pharmacological aspects.Amino Acids. 1996 Mar;10(1):21-47. doi: 10.1007/BF00806091. Amino Acids. 1996. PMID: 24178430
-
Anti-parkinsonian drugs today.Drugs. 1984 Sep;28(3):236-62. doi: 10.2165/00003495-198428030-00002. Drugs. 1984. PMID: 6435991 Review.